![Inactivated Influenza A H1N1 [A/New Cal/20/99]](http://img.creative-biogene.com/main/premade/inactiva-1483.jpg)
Cat.No. : VNV-019
Storage: -80°C Shipping: Dry ice
| Cat. No. | VNV-019 |
| Description | Wild type influenza A H1N1 [A/New Cal/20/99] particles which are inactivated by heat treatment. This product is intended for research use only. |
| Shipping | Dry ice |
| Storage | -80°C |
| Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots. | |
| Mycoplasma | Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination. |
| Purity | Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards. |
| Sterility | The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities. |
| Proviral Identity Confirmation | All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert. |
Here, researchers conjugated the recombinant receptor binding domain (RBD) of the SARS-CoV-2 spike protein to inactivated influenza A virus (Flu) to develop a SARS-CoV-2 virus-like particle (VLP) vaccine with dual protection. This dual vaccine (Flu-RBD) not only induced protective immunity against SARS-CoV-2, but also functioned as an influenza vaccine. The Flu core improved the retention and distribution of the Flu-RBD vaccine in draining lymph nodes and enhanced immunogenicity. In a hamster model of live SARS-CoV-2 infection, two doses of Flu-RBD effectively protected the animals from viral infection. In addition, the Flu-RBD VLPs showed strong neutralizing activity against both SARS-CoV-2 Delta pseudovirus and wild-type influenza A H1N1 inactivated virus in mice. Overall, the Flu-RBD VLP vaccine is a promising candidate vaccine against COVID-19, influenza A, and co-infections.
In this study, the researchers investigated the protective effect of the Flu-RBD vaccine against red fluorescent wild-type influenza A H1N1 inactivated virus (Wild-type influenza A H1N1 (VNV-019) inactivated virus was purchased from Creative Biogene). Compared with the PBS control, Flu-RBD vaccination effectively accelerated the clearance of H1N1 inactivated virus in mice (Figure 1), indicating that the immunogenicity of the influenza vaccine was retained. In addition, they compared the neutralizing activity of Flu-RBD with the clinical standard vaccine LNP@mRNA plus FluZ and found that the protective effect of the Flu-RBD vaccine against H1N1 inactivated virus was similar to that of the LNP@mRNA plus FluZ group, indicating that the Flu-RBD vaccine has the potential to prevent influenza infection (Figure 1).
Figure 1. A comparison of Flu-RBD vaccine and mRNA vaccine plus influenza vaccine against wild-type influenza A H1N1 inactivated virus in mice. (Wang Z, et al., 2023)
A: Influenza A (H1N1), also known as swine flu, is an influenza virus that affects humans, pigs, and other animals. It was first discovered in humans in 2009 and caused a worldwide pandemic.
A: Symptoms of H1N1 flu are similar to those of regular seasonal flu, including fever, cough, sore throat, body aches, headache, chills and fatigue. It can also cause more severe symptoms, such as difficulty breathing and pneumonia.
A: In uncomplicated infections, swine flu usually begins to resolve after three to seven days, but some patients may experience discomfort and coughing for two weeks or longer. Severe swine flu may require hospitalization, extending the length of infection to about 9 to 10 days.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
